ActRIIA Enzyme Activity Inhibitor Screening Kit Size:1000T The approximately 100-aa-long propeptide domain

The approximately 100-aa-long propeptide domain actually contains not only the cleavage moiety but also the mature peptide

Factor IX is activated by another clotting factor

macrophages and eosinophils

with C-terminal 8*His EVTIEAVPPQVAEDNNVLLLVHNLPLALGAFAWYKGNTTAIDKEIARFVPNSNMNFTGQAYSGREIIYSNGSLLFQMITMKDMGVYTLDMTDENYRRTQATVRFHVHPILLKPNITSNNSNPVEGDDSVSLTCDSYTDPDNINYLWSRNGESLSEGDRLKLSEGNRTLTLLNVTRNDTGPYVCETRNPVSVNRSDPFSLNIIYGPDTPIISPSDIYLHPGSNLNLSCHAASNPPAQYFWLINEKPHASSQELFIPNITTNNSGTYTCFVNNSVTGLSRTTVKNITVLEPVTQPFLQVTNTTVKELDSVTLTCLSNDIGANIQWLFNSQSLQLTERMTLSQNNSILRIDPIKREDAGEYQCEISNPVSVRRSNSIKLDIIFDPTQGGLSDGAIAGGGGSHHHHHHHH Expression System HEK293 Molecular Weight 55-90kDa Purity >95% by SDS-PAGE Endotoxin <0

ActRIIA Enzyme Activity Inhibitor Screening Kit Size:1000T The approximately 100-aa-long propeptide domainProduct Specification Species Human Background STX 001, the leading program of Supercede, is a novel oral small molecule Activin Receptor Type II (ACTRII) kinase inhibitor currently in preclinical development for the treatment of obesity. In Phase II clinical studies, inhibition of the ACTRII signaling pathway has been shown to significantly reduce fat while stimulating an increase in lean body mass (muscle). For patients with obesity, achieving